Advanced Courses

ESMO-ESO Courses on Medical Oncology for Medical Students

These annual five-day residential courses enable students to get a full picture of this challenging and interesting professional field before making the choice of their specialisation.

Preceptorship Courses

Apply now to join one of our Preceptorship courses!

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

EFPIA Disclosure Code

Policy News

Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!

Approval is based on results from the BRF117019 study that enrolled patients with rare cancers with BRAF V600E mutation

On 4 May 2018, the US Food and Drug Administration (FDA) approved dabrafenib (TAFINLAR®, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST®, Novartis Pharmaceuticals Corp.) in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Approval was based on a nine-cohort, non-randomised trial, BRF117019 (NCT02034110) enrolling patients with rare cancers with the BRAF V600E mutation, including locally advanced, unresectable, or metastatic anaplastic thyroid cancer with no locoregional treatment options.

The overall response rate was 61% (95% CI: 39%, 80%) in 23 patients with anaplastic thyroid cancer who were evaluable for response. The complete and partial response rates were 4% and 57%, respectively. Response duration was at least 6 months in 64% of responding patients.

The adverse reaction profile among all patients in the trial and among patients in the anaplastic thyroid cancer cohort was similar to that observed in other approved indications.

The recommended doses for anaplastic thyroid cancer are 150 mg of dabrafenib orally twice daily and 2 mg of trametinib orally once daily. Full prescribing information for dabrafenib is available
here and for trametinib
here.

FDA granted this application priority review. FDA also granted breakthrough designation and orphan drug designation for the combination of dabrafenib and trametinib in the anaplastic thyroid cancer with BRAF V600 mutation indication.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.